Samir Parekh, MD, on Investigating Treatment Options for Relapsed Myeloma
The director of translational research in myeloma at the Tisch Cancer Institute discussed investigating sequential T cell redirection therapies.
“Once a patient relapses several times, they start running out of FDA-approved treatment options. And these new, both cellular and bispecific antibody, agents that are on the cusp of being approved are providing hope for those patients. In fact, the initial results from the studies are so promising that they are now being used or tested at least in earlier lines of treatment with combinations of other drugs that are being used to treat myeloma. And that's where our research comes in.”
Sequential use of different T cell redirection therapies, including chimeric antigen receptor (CAR) T-cell therapies and bispecific antibodies (BiAb) led to deep and durable responses in patients with relapsed/refractory multiple myeloma following relapse after BiAb therapy, according to new research out of at Mount Sinai’s Tisch Cancer Institute published in Blood Advances.
CGTLive spoke with Samir Parekh, MD, director of translational research in myeloma and co-leader, Cancer Clinical Investigation program, The Tisch Cancer Institute, and member, Icahn Genomics Institute, Icahn School of Medicine, Mount Sinai, to learn more about the unmet needs for patients whose multiple myeloma relapses several times and the questions that remain to be investigated with sequential T cell redirection therapies.
